COVID-19 vaccine safety update
Testo completo
Documenti correlati
− Le vaccin AZD1222 développé par Astra Zeneca peut être utilisé, conformément à son AMM et dans le cadre de la stratégie vaccinale préalablement définie par la HAS.
In its evaluation the PRAC reviewed published research including the Brinth articles, data from clinical trials and reports of suspected side effects from patients and
In light of the current supply and demand mismatch of COVID vaccines, especially in low and lower middle- income countries with no autonomous development capacity and limited
Author Affiliations: Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California, Oakland (Klein, Lewis, Goddard, Fireman, Zerbo); Marshfield Clinic
PRAC assessed 89 cases reported as glomerulonephritis or nephrotic syndrome worldwide to EudraVigilance (see section 2) by 31 July 2021 (around 918 million doses of Comirnaty
PRAC also considered the assessment carried out in August 2021 by the Medicines & Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK), which concluded that
These data include clinical trial results, reports of suspected side effects in EudraVigilance, epidemiological studies monitoring the safety of the vaccine,
In August 2021, PRAC recommended updating the product information of COVID-19 Vaccine Janssen to include immune thrombocytopenia (ITP) as a side effect, together with a warning